What are the GenBank accession IDs for Haemophilus influenzae type B capsids?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GenBank Accession IDs for Haemophilus influenzae Type b Capsids

The GenBank accession IDs for Haemophilus influenzae type b (Hib) capsular polysaccharide loci include M19995, X78559, and AF549211, which represent the complete cap locus sequences for H. influenzae serotype b strains. 1

Understanding H. influenzae Type b Capsule

H. influenzae exists in two main forms:

  • Encapsulated (typeable) strains - categorized into six serotypes (a-f)
  • Unencapsulated (nontypeable) strains

The type b capsule is a critical virulence factor composed of polyribosylribitol phosphate (PRP) and is encoded by a specific variation of the capsule biosynthesis locus (cap-b). 2, 3

Capsular Locus Organization

The cap locus of H. influenzae type b has a distinctive structure:

  • Central DNA segment specific to serotype b
  • Flanking DNA segments common across all serotypes
  • Contains genes for both capsule synthesis and export 4

A unique feature of the type b capsule locus is:

  • Near-total duplication of the cap region (17 kb region organized as direct repeats)
  • This duplication is not found in other serotypes
  • The duplicated structure appears to confer survival advantages to type b strains 4, 3

Molecular Identification of H. influenzae Type b

The Centers for Disease Control and Prevention (CDC) recommends laboratory confirmation for H. influenzae type b identification, as taxonomy ID alone is insufficient. 2

Key Genes in the Capsular Locus

The complete cap locus sequence reveals:

  • Region I: Contains genes for capsule transport (bexA-D)
  • Region II: Contains serotype-specific genes for capsule biosynthesis
  • Region III: Contains hcsA and hcsB genes involved in post-polymerization modification 1

Modern Identification Methods

Several molecular methods are available for identifying H. influenzae type b:

  • PCR targeting capsule-specific genes - considered the gold standard for serotyping 5
  • Software tools like "hicap" for in silico serotype prediction from genome sequences 6
  • These methods overcome problems of cross-reaction and autoagglutination associated with traditional serotyping 5

Clinical Significance

The accurate identification of H. influenzae type b is critical because:

  • Before effective vaccines, 1 in 200 children developed invasive Hib disease by age 5
  • 60% of these cases involved meningitis with 3-6% mortality
  • 20-30% of meningitis survivors experienced permanent sequelae 7, 2

Vaccination with Hib conjugate vaccines has dramatically reduced type b disease incidence, but accurate identification remains important for:

  • Surveillance of vaccine effectiveness
  • Identifying vaccine failures
  • Monitoring potential emergence of other serotypes 2

Important Considerations

When working with H. influenzae type b capsid sequences:

  • Standard taxonomy IDs typically only identify to species level, not serotype level
  • Biochemical testing can identify H. influenzae to species level but requires both hemin (X factor) and NAD (V factor) for growth
  • Molecular methods are necessary for definitive serotype identification 2

For researchers studying Hib capsids, accessing these GenBank sequences provides valuable reference data for understanding capsule structure, function, and evolution, which remain important despite the success of vaccination programs.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.